ABEO

ZEVASKYN Treatment Timeline: The anticipated start of patient treatment with ZEVASKYN has been shifted to the fourth quarter of 2025 due to the optimization of a release assay, although patient demand remains strong with over 30 eligible patients identified at treatment centers.

Financial Position: As of September 30, 2025, Abeona Therapeutics reported $207.5 million in cash and equivalents, expected to fund operations for over two years, despite a net loss of $5.2 million for the third quarter.

Market Access and Demand: There is significant early market acceptance for ZEVASKYN, with coverage decisions from major commercial health plans covering approximately 60% of RDEB patients, and a permanent J-code established by CMS effective January 1, 2026.

Corporate Developments: Abeona has strengthened its management team with the appointment of a new Head of Clinical Development and has selected its ABO-503 gene therapy for participation in the FDA's Rare Disease Endpoint Advancement Pilot Program.

Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.

KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.

Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.

Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.